<DOC>
	<DOCNO>NCT02422381</DOCNO>
	<brief_summary>This study patient previously-treated advanced non-small cell lung cancer ( NSCLC ) . The study evaluate safety add investigational drug , MK-3475 standard treatment gemcitabine . The study also try identify best dose MK-3475 give combination gemcitabine .</brief_summary>
	<brief_title>MK-3475 Gemcitabine Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This study open-label , non-randomized phase I study , follow open-label non-randomized phase II study . The first cohort patient receive 200 milligram ( mg ) MK-3475 intravenous infusion 21-day period call cycle along Gemcitabine 1250 mg/m2 give Days 1 8 21-day cycle 6 cycle . Patients see study clinic 12 time 126 day evaluation sign symptom may represent drug toxicity . Patients may continue receive MK-3475 ( without gemcitabine ) 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Women men advance , histologically proven NSCLC . Patients must receive least one three prior systemic therapy advance disease . Any toxicity relate prior therapy , opinion investigator , would potentially worsen antiPD1 therapy gemcitabine resolve less Grade 1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Women childbearing potential must negative pregnancy test Ability give inform consent comply protocol . Anticipated survival minimum 3 month . Prior therapy investigational agent must complete least 3 week prior study enrollment . Patients must normal organ marrow function see protocoldefined blood test result Archived tumor tissue ( minimum 8 slide paraffinembedded tumor tissue ) available Measurable disease RECIST 1.1 criterion . Treated brain metastasis allow , provide asymptomatic . Radiation symptomatic lesion outside Central nervous system ( CNS ) must complete least 2 week prior study enrollment . Prior therapy antiPD1 , antiPDL1 , antiCTLA4 antibody . Prior therapy gemcitabine . Prior complication radiation , history radiation pneumonitis pulmonary edema , opinion investigator , may risk increase toxicity antiPD1 therapy . Active autoimmune disease except vitiligo stable hypothyroidism . Active ongoing steroid use , except nonsystemically absorb treatment ( inhaled topical steroid therapy asthma , cardiopulmonary disease ( COPD ) , allergic rhinitis ) . Active malignancy , except control basal cell skin carcinoma . HIV positive and/or Hepatitis B C positive . Other medical psychiatric condition opinion Principal Investigator would preclude safe participation protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>lung cancer</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Anti-PD-1</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>